Endoscopic Retrograde Cholangiopancreatography Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product (Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices, Others), By Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, Pancreatic Duct Dilation), By End User (Hospitals, Outpatient Facilities), By Region, & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.23 Billion
CAGR (2026-2031)	8.76%
Fastest Growing Segment	Endotherapy Devices
Largest Market	North America
Market Size (2031)	USD 3.69 Billion

Market Overview

The Global Endoscopic Retrograde Cholangiopancreatography Market will grow from USD 2.23 Billion in 2025 to USD 3.69 Billion by 2031 at a 8.76% CAGR. Endoscopic Retrograde Cholangiopancreatography is a specialized medical procedure that combines upper gastrointestinal endoscopy with radiographic imaging to treat disorders of the bile and pancreatic ducts. The expansion of this market is fundamentally driven by the rising prevalence of biliary diseases and an aging global population that increasingly requires therapeutic interventions. These demographic and epidemiological factors create a sustained demand for effective diagnostic and treatment modalities which underpins the financial growth of the sector.

However, the market faces a substantial challenge regarding the scarcity of skilled physicians capable of performing this complex technique safely. This lack of expertise can lead to bottlenecks in service delivery and limit procedure volumes in emerging regions. According to the American Cancer Society, in 2025, an estimated 67,440 people will be diagnosed with pancreatic cancer in the United States. This data illustrates the critical necessity for these procedures and highlights the burden of disease that continues to drive the utilization of endoscopic solutions.

Key Market Drivers

The surging adoption of single-use duodenoscopes is fundamentally altering the market landscape as healthcare providers prioritize infection control and operational efficiency to mitigate cross-contamination risks associated with reusable devices. This transition is further accelerated by regulatory recommendations and the financial benefits of eliminating complex reprocessing workflows which significantly reduces the total cost of ownership for hospitals. According to Ambu A/S, November 2025, in the 'Annual Report 2024/25', the company recorded an organic growth rate of 15.4 percent in its Endoscopy Solutions business which underscores the rapid shift toward disposable technologies. The demand for these sterile alternatives ensures sustained market expansion as facilities replace legacy inventory to enhance patient safety standards.

The rising prevalence of pancreatic and biliary disorders serves as the primary clinical engine driving the global procedure volume for endoscopic interventions. An aging global population and lifestyle changes are contributing to a higher incidence of conditions such as gallstones and malignancies that necessitate precise diagnostic and therapeutic capabilities. According to the National Institutes of Health, February 2025, in the article 'Trends in the Global Incidence of Pancreatic Cancer', the global burden of the disease reached an estimated 510,922 new cases in the 2022 reference year with projections indicating a continued upward trajectory. This epidemiological pressure compels manufacturers to scale operations and innovate to meet the growing need for effective treatment. Reflecting this broader sectoral momentum, According to Boston Scientific, in 2025, the corporation reported full year 2024 net sales of 16.75 billion dollars which represents a 17.6 percent increase driven by the robust performance of its medical and surgical portfolio.

Download Free Sample Report

Key Market Challenges

The scarcity of skilled physicians capable of performing Endoscopic Retrograde Cholangiopancreatography (ERCP) stands as a significant impediment to the growth of the Global Endoscopic Retrograde Cholangiopancreatography Market. This procedure requires a high level of technical proficiency and extensive specialized training, which limits the pool of qualified professionals. As the prevalence of biliary and pancreatic disorders rises, the inability of healthcare systems to scale their workforce at a commensurate rate results in critical bottlenecks. These service gaps lead to longer wait times for patients and reduced procedure volumes, which directly constrains the revenue potential of the market.

Furthermore, the rigorous learning curve associated with ERCP discourages many new practitioners from entering the field, while the existing workforce faces increasing pressure. This workforce strain is exacerbated by demographic shifts among medical professionals themselves. According to the Association of American Medical Colleges, in 2024, the United States healthcare system was projected to face a total physician shortage of up to 86,000 by 2036, a deficit that severely impacts complex specialties such as gastroenterology. This widening gap between the supply of skilled endoscopists and the growing demand for therapeutic interventions restricts market expansion, particularly in underserved and emerging regions where training infrastructure is already limited.

Key Market Trends

The integration of artificial intelligence for image analysis is becoming a transformative force within the ERCP landscape, fundamentally enhancing diagnostic precision and procedural decision-making. These advanced algorithms are being deployed to assist endoscopists in the real-time detection of biliary lesions and the differentiation of indeterminate strictures, which significantly reduces the inter-observer variability associated with traditional fluoroscopic interpretation. This technological evolution extends beyond diagnostics to predict post-procedure complications, thereby enabling more personalized patient management strategies. According to the American Medical Association, January 2025, in a national survey report on digital health trends, 66 percent of physicians utilized artificial intelligence tools in their practice during 2024, representing a 78 percent increase from the previous year, a surge that signals the rapid permeation of data-driven capabilities into specialized fields like gastroenterology.

Simultaneously, the market is witnessing profound advancements in digital cholangioscopy and high-definition visualization systems. This trend marks a critical departure from reliance on indirect radiographic imaging, allowing practitioners to directly visualize the bile and pancreatic ducts with superior clarity for targeted biopsies and complex lithotripsy. The rising clinical demand for these sophisticated optical platforms is driven by the necessity to accurately stage malignancies and manage difficult stone burdens without repeated interventions. Reflecting this robust demand for next-generation endoscopic technologies, According to Olympus Corporation, November 2024, in the 'Consolidated Financial Results for the Six Months Ended September 30, 2024', the company’s Endoscopic Solutions Business recorded a revenue increase of 10.3 percent, a growth trajectory primarily attributed to the strong sales performance of its advanced visualization systems in North America and Europe.

Segmental Insights

Within the Global Endoscopic Retrograde Cholangiopancreatography Market, the Endotherapy Devices segment is projected to witness the fastest growth. This positive trajectory is largely attributed to the increasing preference for minimally invasive procedures to treat rising biliary and pancreatic obstructions. Additionally, heightened scrutiny from regulatory bodies such as the U.S. Food and Drug Administration regarding infection control has accelerated the clinical adoption of single-use accessories to mitigate cross-contamination risks. Consequently, the frequent requirement for disposable consumables, including sphincterotomes and stents, supports the rapid expansion of this segment relative to capital-intensive equipment.

Regional Insights

North America maintains a leading position in the Global Endoscopic Retrograde Cholangiopancreatography Market, primarily due to the rising incidence of pancreatic and biliary diseases like gallstones. This regional strength is reinforced by a robust healthcare infrastructure that facilitates the widespread adoption of minimally invasive procedures. Additionally, comprehensive reimbursement frameworks established by the Centers for Medicare & Medicaid Services improve patient affordability and access to care. The market is further sustained by the consistent approval of medical technologies by the U.S. Food and Drug Administration, which supports clinical capabilities in managing complex digestive disorders.

Recent Developments

• In August 2024, PENTAX Medical, a division of the HOYA Group, obtained FDA clearance for the compatibility of its DEC Duodenoscope (ED34-i10T2s) with the STERRAD 100NX Sterilizer from Advanced Sterilization Products. This regulatory milestone established the device as the first flexible gastrointestinal endoscope to be approved for use with hydrogen peroxide gas plasma sterilization technology. The clearance provided healthcare facilities with a validated, efficient reprocessing option intended to mitigate the risk of bacterial contamination, which has been a persistent concern in the reuse of complex ERCP instruments. This development highlighted the company’s commitment to enhancing patient safety and operational efficiency in gastroenterology departments by offering more reliable sterilization workflows for their reusable duodenoscope portfolio.
• In August 2024, KARL STORZ United States and Fujifilm Healthcare Americas Corporation entered into a strategic commercial collaboration to jointly market their respective endoscopic portfolios in the U.S. market. The partnership combined Fujifilm’s flexible gastrointestinal endoscopes, including those used for pancreaticobiliary procedures, with KARL STORZ’s integrated operating room solutions. This initiative aimed to provide comprehensive technology packages to ambulatory surgery centers and hospital-based interventional GI suites, facilitating better workflow integration and data management. By leveraging the strengths of both organizations, the collaboration sought to modernize endoscopy environments and improve clinical efficiency for surgeons and gastroenterologists performing complex therapeutic interventions such as ERCP and other minimally invasive procedures.
• In April 2024, Ambu A/S received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for its next-generation single-use duodenoscope, the aScope Duodeno 2, alongside the accompanying aBox 2 endoscopy system. This approval marked a significant advancement in the disposable ERCP device market, as the solution was designed to address complex infection control challenges associated with reusable endoscopes. The aScope Duodeno 2 featured improvements in ergonomics and performance to handle the demanding nature of Endoscopic Retrograde Cholangiopancreatography procedures. By offering a fully sterile, single-use option, the company aimed to support healthcare facilities in transitioning towards safer endoscopic practices and reducing the risk of patient-to-patient cross-contamination.
• In January 2024, Canon Medical Systems Corporation and Olympus Corporation announced a strategic business alliance to collaborate on Endoscopic Ultrasound Systems (EUS), a modality closely linked to the management of pancreatobiliary disorders. Under this agreement, Canon Medical Systems agreed to develop and manufacture advanced diagnostic ultrasound systems, specifically the Aplio i800, while Olympus Corporation took responsibility for the sales and marketing efforts of the combined solutions. This collaboration aimed to integrate Canon’s high-quality ultrasound imaging technology with Olympus’s established ultrasound endoscopes to provide enhanced diagnostic precision for healthcare professionals. The partnership focused on delivering superior imaging quality to support early detection and diagnosis of diseases, initially targeting markets in Japan and Europe with plans for global expansion.

Key Market Players

• Olympus Corporation
• CONMED Corporation
• Boston Scientific Corporation
• Medtronic PLC
• TeleMed Systems, Inc.
• Ambu A/S
• FUJIFILM Holdings Corporation
• HOBBS MEDICAL INC
• Cook Group Incorporated
• HOYA Corporation

By Product	By Procedure	By End User	By Region
Endoscopes Endotherapy Devices Visualization Systems Energy Devices Others	Biliary Sphincterotomy Biliary Stenting Biliary Dilatation Pancreatic Sphincterotomy Pancreatic Duct Stenting Pancreatic Duct Dilation	Hospitals Outpatient Facilities	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Endoscopic Retrograde Cholangiopancreatography Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Endoscopic Retrograde Cholangiopancreatography Market, By Product:

• Endoscopes
• Endotherapy Devices
• Visualization Systems
• Energy Devices
• Others

• Endoscopic Retrograde Cholangiopancreatography Market, By Procedure:

• Biliary Sphincterotomy
• Biliary Stenting
• Biliary Dilatation
• Pancreatic Sphincterotomy
• Pancreatic Duct Stenting
• Pancreatic Duct Dilation

• Endoscopic Retrograde Cholangiopancreatography Market, By End User:

• Hospitals
• Outpatient Facilities

• Endoscopic Retrograde Cholangiopancreatography Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE